Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platonin is a **cyanine photosensitizing dye** with notable **antioxidant, anti-inflammatory, immunomodulating,** and **antiplatelet** properties. It has been used to treat trauma, ulcers, and acute inflammation, and has shown neuroprotective effects in preclinical models of ischemic stroke, as well as beneficial effects in animal models of sepsis, heatstroke, ischemia-reperfusion injury, and transplant survival. Mechanistically, platonin acts as a free radical scavenger, suppresses the production of inflammatory cytokines (including interleukin-1β, IL-6, tumor necrosis factor-α, and inducible nitric oxide synthase) via inhibition of transcription factors like nuclear factor-kB (NF-κB) and activator protein-1 (AP-1), and inhibits signaling pathways such as mitogen-activated protein kinases (MAPKs: ERK, JNK, p38 MAPK). Platonin also inhibits platelet aggregation through inactivation of JNK phosphorylation in platelets. Clinically, platonin has been reported for use in immune diseases such as juvenile rheumatoid arthritis and polyarteritis nodosa, mainly in certain Asian countries[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platonin.